Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 1998 December;10(4) > Minerva Biotecnologica 1998 December;10(4):138-45

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

  MONOCLONAL ANTIBODIES FOR IN VIVO APPLICATIONS - PART II


Minerva Biotecnologica 1998 December;10(4):138-45

lingua: Inglese

Effectiveness of ­local radio­im­mu­no­ther­a­py of ­high ­grade malig­nant gli­o­mas ­with ­anti-tenas­cin mono­clo­nal anti­bod­ies

Riva P. 1, Franceschi G. 1, Frattarelli M. 2, Riva N. 3, Guiducci G. 2, Cremonini A. M. 2, Giuliani G. 1, Casi M. 4

1 Dept of Nuclear Medicine and Istituto Oncologico Romagnolo;
2 Neurosurgery Department “M. Bufalini” Hospital Cesena;
3 Department “Pierantoni” Hospital Forlì, Italy;
4 Medical Oncology


FULL TEXT  


Background. The ­loco-region­al radio­im­mu­no­ther­a­py may con­trol malig­nant gli­omas and, in par­tic­u­lar gli­o­blas­to­mas ­whose prog­no­sis is ­very dis­mal.
Methods. 152 ­patients (91 in 131I and 61 in 90Y stud­ies) ­received ­loco-region­al-radioimmunotherapy (RIT). They had: 2 olig­o­den­dro­gli­o­ma, 7 ana­plas­tic olig­o­den­dro­gli­o­ma, 18 ana­plas­tic astro­cy­to­ma and 124 gli­o­blas­to­ma. 79 ­were new­ly diag­nosed ­tumours, 93 had recur­rent ­lesions. Two 131I or 90Y ­labelled anti­te­nas­cin mono­clo­nal anti­bod­ies BC-2 and BC-4, ­were util­ised. The ­patients had radio­im­mu­no­ther­a­py fol­low­ing cus­tomary reg­i­mens. The radio­ac­tive Mabs ­were ­infused ­into the sur­gi­cal cra­ter.
Results. The accre­tion of the radio­phar­ma­ceu­ti­cal in the neo­plas­tic ­area was remark­able. The ­mean radi­a­tion ­dose to the ­tumour per admin­is­tra­tion was 300 Gy in 131I ­group and 600 Gy in 90Y sub­set. In 131I gli­o­blas­to­ma cas­es we reg­is­tered: 10 ­stable dis­eas­es (SD), 9 par­tial respons­es (PR), 23 no evi­denc­es of dis­ease (NED) and 1 com­plete ­response (CR). In 90Y gli­o­blas­to­ma ­class we doc­u­ment­ed 14 PD, 4 SD, 6 PR and 9 NED. In 131I gli­o­blas­to­ma sub­set, the ­median sur­vi­val was 19 ­months (17 ­months in cas­es ­with ­bulky ­lesions and 25 ­months in ­patients ­with min­i­mal dis­ease). In 90Y ­group the ­median sur­vi­val of gli­o­blas­to­ma was 18 ­months (16 in cas­es ­with ­bulky ­lesions and 31 in ­patients ­with ­small or min­i­mal dis­ease). The ­patients ­with olig­o­den­dro­gli­o­ma, ana­plas­tic olig­o­den­drog­li­oma and ana­plas­tic astro­cy­to­ma, ­obtained bet­ter respons­es.
Conclusions. The ­loco-region­al RIT was ­well tol­er­at­ed and ­proved its effec­tive­ness, main­ly in cas­es ­with ­reduced ­tumour bur­den ­after the cus­to­mary reg­i­mens.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail